[go: up one dir, main page]

DK1601689T3 - Oprensningsfremgangsmåde for bakterielt cytolysin - Google Patents

Oprensningsfremgangsmåde for bakterielt cytolysin

Info

Publication number
DK1601689T3
DK1601689T3 DK04719447T DK04719447T DK1601689T3 DK 1601689 T3 DK1601689 T3 DK 1601689T3 DK 04719447 T DK04719447 T DK 04719447T DK 04719447 T DK04719447 T DK 04719447T DK 1601689 T3 DK1601689 T3 DK 1601689T3
Authority
DK
Denmark
Prior art keywords
purification procedure
bacterial cytolysin
cytolysin purification
bacterial
procedure
Prior art date
Application number
DK04719447T
Other languages
Danish (da)
English (en)
Inventor
Ralph Biemans
Emmanuel Mertens
Carine Goraj
Anne Vandercammen
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305791A external-priority patent/GB0305791D0/en
Priority claimed from GB0305792A external-priority patent/GB0305792D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK1601689T3 publication Critical patent/DK1601689T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK04719447T 2003-03-13 2004-03-11 Oprensningsfremgangsmåde for bakterielt cytolysin DK1601689T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0305791A GB0305791D0 (en) 2003-03-13 2003-03-13 Detoxification process
GB0305792A GB0305792D0 (en) 2003-03-13 2003-03-13 Purification Process
PCT/EP2004/002641 WO2004081515A2 (fr) 2003-03-13 2004-03-11 Procédé de purification

Publications (1)

Publication Number Publication Date
DK1601689T3 true DK1601689T3 (da) 2008-03-25

Family

ID=32992596

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04719447T DK1601689T3 (da) 2003-03-13 2004-03-11 Oprensningsfremgangsmåde for bakterielt cytolysin

Country Status (22)

Country Link
US (3) US8084235B2 (fr)
EP (1) EP1601689B1 (fr)
JP (2) JP4597123B2 (fr)
KR (1) KR101052996B1 (fr)
CN (1) CN101818185B (fr)
AU (2) AU2004219910B2 (fr)
BR (1) BRPI0408094A (fr)
CA (2) CA2518669C (fr)
CY (1) CY1107134T1 (fr)
DE (1) DE602004010376T2 (fr)
DK (1) DK1601689T3 (fr)
EG (1) EG24449A (fr)
ES (1) ES2295836T3 (fr)
IL (1) IL210984A0 (fr)
IS (1) IS2587B (fr)
MA (1) MA27666A1 (fr)
MX (1) MXPA05009579A (fr)
NO (1) NO336672B1 (fr)
NZ (1) NZ541969A (fr)
PT (1) PT1601689E (fr)
RU (1) RU2340627C2 (fr)
WO (1) WO2004081515A2 (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1601689B1 (fr) 2003-03-13 2007-11-28 GlaxoSmithKline Biologicals S.A. Procede de purification pour cytolise bactérien
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
MX2007011706A (es) 2005-03-23 2007-12-11 Oculus Innovative Sciences Inc Metodo para tratar quemaduras de segundo y tercer grado utilizando solucion de agua con potencial oxido reductor.
PE20070163A1 (es) 2005-06-27 2007-03-01 Glaxosmithkline Biolog Sa Composicion inmunogenica de conjugados de sacaridos de n. meningitidis
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3020411A1 (fr) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccin
AU2007205863B2 (en) 2006-01-20 2013-06-20 Oculus Innovative Sciences, Inc. Methods of treating or preventing peritonitis with oxidative reductive potential water solution
AU2007293672B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
WO2008127179A1 (fr) * 2007-04-16 2008-10-23 Lunds Universitets Utvecklingsaktiebolag Vaccin à protéine de fusion
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
MX2009013949A (es) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
MX2010011412A (es) 2008-04-16 2010-11-12 Glaxosmithkline Biolog Sa Vacuna.
AU2009286769A1 (en) * 2008-08-28 2010-03-04 Glaxosmithkline Biologicals S.A. Vaccine
CN102413838A (zh) 2009-04-30 2012-04-11 科勒制药集团有限公司 肺炎球菌疫苗及其用途
WO2010132833A1 (fr) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Compositions vaccinales contre streptococcus et méthodes d'utilisation associées
MX386504B (es) 2009-06-15 2025-03-19 Sanfer Farma S A P I De C V Solucion que contiene acido hipocloroso y metodos para usar la misma.
AU2010290931B2 (en) 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
EP3199177A1 (fr) 2009-10-30 2017-08-02 GlaxoSmithKline Biologicals S.A. Purification de saccharides capsulaires de staphylococcus aureus de type 5 et de type 8
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2012131504A1 (fr) 2011-03-02 2012-10-04 Pfizer Inc. Vaccin à base de pcsk9
TWI671313B (zh) * 2011-04-22 2019-09-11 惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
KR20140033127A (ko) 2011-05-17 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애에 대한 백신
ES2763415T3 (es) 2012-09-19 2020-05-28 Univ Osaka Vacuna neumocócica que contiene proteína A superficial neumocócica
US10287542B2 (en) 2012-11-30 2019-05-14 Bioneer Corporation Apparatus for automatically preparing cell-free proteins and method for preparing proteins using same
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
SG11201604728XA (en) 2014-01-21 2016-08-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
DK3096786T3 (da) 2014-01-21 2021-08-02 Pfizer Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf
ES2883343T3 (es) 2014-01-21 2021-12-07 Pfizer Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10668164B2 (en) 2014-02-14 2020-06-02 Pfizer Inc. Immunogenic glycoprotein conjugates
MX395525B (es) 2015-01-15 2025-03-25 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
US9218427B1 (en) * 2015-01-21 2015-12-22 Maana, Inc. Dynamic semantic models having multiple indices
JP2018513218A (ja) * 2015-04-16 2018-05-24 インベントプライズ リミテッド ライアビリティ カンパニー 百日咳菌免疫原性ワクチン組成物
BR112018000087A2 (pt) 2015-07-21 2018-09-04 Pfizer Inc. composições imunogênicas que compreendem antígenos de sacarídeos capsulares conjugados, kits que compreendem as mesmas e usos das mesmas
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (fr) 2015-11-20 2023-10-10 Pfizer Inc. Compositions immunogenes destinees a etre utilisees dans des vaccins pneumococciques
GB201603029D0 (en) * 2016-02-22 2016-04-06 Glaxosmithkline Biolog Sa Vaccine
EP3493840B1 (fr) 2016-08-05 2022-08-24 Sanofi Pasteur Inc. Composition d'un conjugué polysaccharide-protéine pneumococcique multivalent
CN109862908B (zh) 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US20190360013A1 (en) * 2016-12-02 2019-11-28 President And Fellows Of Harvard College Processive Template Independent DNA Polymerase Variants
US11998599B2 (en) 2016-12-30 2024-06-04 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
EP3576784B1 (fr) 2017-01-31 2025-09-24 Merck Sharp & Dohme LLC Procédés de fabrication de conjugués polysaccharides-protéine
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
CN110392690B (zh) 2017-02-24 2024-01-30 默沙东有限责任公司 肺炎球菌缀合物疫苗制剂
KR20240018697A (ko) 2017-06-10 2024-02-13 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
EP3678654B1 (fr) 2017-09-07 2024-06-26 Merck Sharp & Dohme LLC Polysaccharides antipneumococciques et leur utilisation dans des conjugués immunogènes polysaccharide-protéine porteuse
CN117982633A (zh) 2017-12-06 2024-05-07 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
CA3089007A1 (fr) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Composition de conjugues polysaccharide-proteine pneumococcique multivalents
IL276229B2 (en) 2018-02-05 2024-01-01 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3782642A4 (fr) 2018-04-18 2022-04-13 SK Bioscience Co., Ltd. Polysaccharides capsulaires de streptococcus pneumoniae et conjugués immunogènes de ceux-ci
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020120569A2 (fr) 2018-12-12 2020-06-18 Glaxosmithkline Biologicals Sa Protéines porteuses modifiées pour glycosylation à liaison o
CA3120922A1 (fr) 2018-12-12 2020-06-18 Pfizer Inc. Conjugues polysaccharide-proteine immunogenes a heteroantigenes multiples et leurs utilisations
CR20210333A (es) 2018-12-19 2021-08-18 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN114728050A (zh) 2019-07-31 2022-07-08 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法
CN114667343A (zh) 2019-11-01 2022-06-24 辉瑞大药厂 大肠杆菌组合物及其方法
WO2021165847A1 (fr) 2020-02-21 2021-08-26 Pfizer Inc. Purification de saccharides
CN115605498A (zh) 2020-02-23 2023-01-13 辉瑞公司（Us） 大肠杆菌组合物及其方法
EP4192499A4 (fr) 2020-08-10 2024-09-25 Inventprise, Inc. Vaccins glycoconjugués pneumococciques multivalents contenant un sérotype 24f émergent
CA3199094A1 (fr) 2020-10-22 2022-04-28 Pfizer Inc. Procedes de purification de polysaccharides bacteriens
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023005221A (es) 2020-11-04 2023-05-16 Pfizer Composiciones inmunogenicas para uso en vacunas neumococicas.
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234416A1 (fr) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination contre des infections à pneumocoque et à covid-19
CA3218544A1 (fr) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination contre des infections bacteriennes et a betacoronavirus
WO2022249107A2 (fr) 2021-05-28 2022-12-01 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
EP4346892A2 (fr) 2021-05-28 2024-04-10 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
KR20240128715A (ko) 2022-01-13 2024-08-26 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2023161817A1 (fr) 2022-02-25 2023-08-31 Pfizer Inc. Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
CN119317445A (zh) 2022-05-11 2025-01-14 辉瑞公司 用于生产含有防腐剂的疫苗制剂的方法
WO2024084397A1 (fr) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination contre infections à pneumocoques et à covid-19
WO2024110827A1 (fr) 2022-11-21 2024-05-30 Pfizer Inc. Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
CN120265317A (zh) 2022-11-22 2025-07-04 辉瑞公司 包含经缀合的荚膜糖抗原的免疫原性组合物及其用途
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
EP4661911A1 (fr) 2023-02-10 2025-12-17 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (fr) 2023-04-24 2024-10-31 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées
WO2024238731A1 (fr) 2023-05-18 2024-11-21 Merck Sharp & Dohme Llc Composés et formulations d'adjuvant utiles dans des vaccins pneumococciques
CN121263203A (zh) 2023-05-19 2026-01-02 葛兰素史克生物有限公司 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法
WO2025057078A1 (fr) 2023-09-14 2025-03-20 Pfizer Inc. Compositions immunogènes adjuvantées comprenant des antigènes saccharidiques capsulaires pneumococciques conjugués et leurs utilisations
WO2025080765A1 (fr) * 2023-10-12 2025-04-17 Rutgers, The State University Of New Jersey Méthodes pour administrer une charge protéine/peptide exogène à un cytosol cellulaire et utilisations associées
US20250161420A1 (en) 2023-11-16 2025-05-22 Merck Sharp & Dohme Llc Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease
WO2025133971A1 (fr) 2023-12-23 2025-06-26 Pfizer Inc. Procédés améliorés de production de glycoconjugués de saccharides capsulaires de bactéries
WO2025186705A2 (fr) 2024-03-06 2025-09-12 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2025191415A1 (fr) 2024-03-11 2025-09-18 Pfizer Inc. Compositions immunogènes comprenant des saccharides conjugués d'escherichia coli et leurs utilisations
WO2025219904A1 (fr) 2024-04-19 2025-10-23 Pfizer Inc. Procédés améliorés de production de glycoconjugués par amination réductrice dans un solvant aprotique
WO2025219908A2 (fr) 2024-04-19 2025-10-23 Pfizer Inc. Procédés de fermentation de milieux et de fermentation pour la production de polysaccharides dans une culture de cellules bactériennes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
ATE205534T1 (de) 1988-12-16 2001-09-15 Nederlanden Staat Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
DE4133707A1 (de) * 1991-10-11 1993-04-15 Behringwerke Ag Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung
GB9216351D0 (en) * 1992-07-31 1992-09-16 Wellcome Found Vaccine production
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
DE69636935T2 (de) 1995-01-27 2007-11-22 Genencor International, Inc., Palo Alto Verfahren zur extraktion von enzymen unter verwendung von tensiden
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
US5667786A (en) * 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
WO1999003884A2 (fr) * 1997-07-21 1999-01-28 North American Vaccine, Inc. Compositions de pneumolysine immunogene modifiee utiles en tant que vaccins
EP1880735A3 (fr) * 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccin
JP4132694B2 (ja) * 2000-03-10 2008-08-13 独立行政法人科学技術振興機構 受容体認識部位が保存された生理活性物質の誘導体及びその使用方法
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP1601689B1 (fr) 2003-03-13 2007-11-28 GlaxoSmithKline Biologicals S.A. Procede de purification pour cytolise bactérien
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process

Also Published As

Publication number Publication date
CA2518669A1 (fr) 2004-09-23
BRPI0408094A (pt) 2006-02-14
US20070026010A1 (en) 2007-02-01
NO336672B1 (no) 2015-10-19
US8815254B2 (en) 2014-08-26
MXPA05009579A (es) 2005-11-17
AU2004219910B2 (en) 2010-06-17
CN101818185A (zh) 2010-09-01
NO20054134L (no) 2005-10-04
US20110311577A1 (en) 2011-12-22
WO2004081515A3 (fr) 2004-11-11
US8084235B2 (en) 2011-12-27
JP4597123B2 (ja) 2010-12-15
IS2587B (is) 2010-02-15
MA27666A1 (fr) 2005-12-01
NZ541969A (en) 2008-01-31
CY1107134T1 (el) 2012-10-24
PT1601689E (pt) 2008-01-04
IS7993A (is) 2005-08-18
AU2004219910A1 (en) 2004-09-23
JP2006520205A (ja) 2006-09-07
RU2005125832A (ru) 2006-04-27
US8309327B2 (en) 2012-11-13
DE602004010376T2 (de) 2008-10-23
EP1601689A2 (fr) 2005-12-07
NO20054134D0 (no) 2005-09-06
IL210984A0 (en) 2011-04-28
KR20050111357A (ko) 2005-11-24
JP5683866B2 (ja) 2015-03-11
RU2340627C2 (ru) 2008-12-10
US20140010843A1 (en) 2014-01-09
CA2518669C (fr) 2014-07-29
EP1601689B1 (fr) 2007-11-28
ES2295836T3 (es) 2008-04-16
DE602004010376D1 (de) 2008-01-10
AU2010212257B2 (en) 2012-08-30
HK1086013A1 (en) 2006-09-08
JP2010259448A (ja) 2010-11-18
EG24449A (en) 2009-07-13
CA2812817A1 (fr) 2004-09-23
AU2010212257A1 (en) 2010-09-02
CN101818185B (zh) 2016-05-25
CA2812817C (fr) 2016-12-20
WO2004081515A2 (fr) 2004-09-23
KR101052996B1 (ko) 2011-07-29

Similar Documents

Publication Publication Date Title
DK1601689T3 (da) Oprensningsfremgangsmåde for bakterielt cytolysin
ECSP066436A (es) Compuestos heterociclicos fusionados
SE0301569D0 (sv) Novel compounds
NO2016001I2 (no) Trastuzumab emtansin
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
DE50310488D1 (de) Längsträger
SE0301567L (sv) Robot system
DK1524928T3 (da) Tandbørster
DK1694705T3 (da) Interleukin-10-antistoffer
ATE333815T1 (de) Zahnbürste
ATE453394T1 (de) Multipartikeln
NO20055459D0 (no) Prosesser
DK1597007T3 (da) Borepatron
IS8089A (is) Efnasambönd
DE502004002283D1 (de) Pasteurisierungsanlage
EP1670503A4 (fr) Procede d'immunotherapie
NO20031736D0 (no) Forbindelser
NO20055097D0 (no) Krystallinske N-formyl-hydroksylaminforbindelser
ITVI20030028U1 (it) Raccordo per tubazioni
SI1601689T1 (sl) Cistilni postopek za bakterijski citolizin
SE0303206D0 (sv) Reningsanordning
SE0300118D0 (sv) Novel Compounds
SE0302667D0 (sv) Novel Compounds
SE0300388D0 (sv) Novel compounds
ITBZ20030062A1 (it) Doppiogancio fermacanne per la viticoltura